EyePoint Pharmaceuticals (EYPT) Financials

$5.68 +0.08 (+1.43%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$5.60 -0.08 (-1.41%)

As of 05/23/2025 06:23 PM Eastern

Annual Income Statements for EyePoint Pharmaceuticals

This table shows EyePoint Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-131	-71	-102
Consolidated Net Income / (Loss)	-131	-71	-102
Net Income / (Loss) Continuing Operations	-131	-71	-102
Total Pre-Tax Income	-131	-71	-102
Total Operating Income	-146	-75	-100
Total Gross Profit	43	46	33
Total Revenue	43	46	41
Operating Revenue	43	46	41
Total Cost of Revenue	0.00	0.00	8.33
Total Operating Expenses	189	121	133
Selling, General & Admin Expense	52	40	35
Marketing Expense	0.13	12	26
Research & Development Expense	133	65	50
Amortization Expense	0.00	0.00	2.05
Other Operating Expenses / (Income)	3.71	4.63	-
Impairment Charge	0.00	0.00	21
Total Other Income / (Expense), net	15	4.36	-2.62
Interest Expense	0.01	2.59	4.75
Other Income / (Expense), net	15	6.95	2.13
Income Tax Expense	0.09	0.08	0.00
Basic Earnings per Share	($2.32)	($1.82)	($2.74)
Weighted Average Basic Shares Outstanding	56.30M	38.90M	37.32M
Diluted Earnings per Share	($2.32)	($1.82)	($2.74)
Weighted Average Diluted Shares Outstanding	56.30M	38.90M	37.32M
Weighted Average Basic & Diluted Shares Outstanding	68.73M	49.83M	34.30M

This table shows EyePoint Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-41	-29	-31	-29	-14	-13	-23	-21	-43	-18
Consolidated Net Income / (Loss)	-41	-29	-31	-29	-14	-13	-23	-21	-43	-18
Net Income / (Loss) Continuing Operations	-41	-29	-31	-29	-14	-13	-23	-21	-43	-18
Total Pre-Tax Income	-41	-29	-31	-29	-14	-13	-23	-21	-43	-18
Total Operating Income	-45	-33	-35	-33	-16	-14	-23	-22	-44	-18
Total Gross Profit	14	9.79	8.08	11	18	14	7.31	7.04	3.98	10
Total Revenue	12	11	9.48	12	14	15	9.11	7.68	11	10
Operating Revenue	12	11	9.48	12	14	15	9.11	7.68	11	10
Total Cost of Revenue	-2.90	0.74	1.40	0.76	-3.63	1.20	1.79	0.64	6.55	0.00
Total Operating Expenses	60	43	43	44	34	28	30	29	48	28
Selling, General & Admin Expense	13	13	13	14	11	11	9.06	9.24	8.50	9.21
Marketing Expense	0.05	0.02	0.05	0.01	0.19	0.48	5.29	5.74	5.92	6.02
Research & Development Expense	43	30	30	30	18	17	16	14	16	11
Total Other Income / (Expense), net	3.93	3.39	3.72	4.04	2.34	1.79	-0.16	0.39	0.29	-0.02
Interest Expense	0.01	0.00	0.00	0.00	-	0.00	1.78	0.81	0.78	0.66
Other Income / (Expense), net	3.94	3.39	3.72	4.04	2.34	1.79	1.62	1.20	1.07	0.64
Basic Earnings per Share	($0.65)	($0.54)	($0.58)	($0.55)	($0.32)	($0.33)	($0.61)	($0.56)	($1.16)	($0.49)
Weighted Average Basic Shares Outstanding	56.30M	54.45M	53.21M	52.91M	38.90M	38.34M	37.58M	37.49M	37.32M	37.34M
Diluted Earnings per Share	($0.65)	($0.54)	($0.58)	($0.55)	($0.32)	($0.33)	($0.61)	($0.56)	($1.16)	($0.49)
Weighted Average Diluted Shares Outstanding	56.30M	54.45M	53.21M	52.91M	38.90M	38.34M	37.58M	37.49M	37.32M	37.34M
Weighted Average Basic & Diluted Shares Outstanding	68.73M	68.25M	53.52M	52.08M	49.83M	35.31M	34.98M	34.30M	34.30M	34.08M

This table details how cash moves in and out of EyePoint Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-182	186	-83
Net Cash From Operating Activities	-126	1.88	-65
Net Cash From Continuing Operating Activities	-126	1.88	-65
Net Income / (Loss) Continuing Operations	-131	-71	-102
Consolidated Net Income / (Loss)	-131	-71	-102
Depreciation Expense	1.54	0.46	0.40
Amortization Expense	-5.95	-0.86	1.49
Non-Cash Adjustments To Reconcile Net Income	37	14	38
Changes in Operating Assets and Liabilities, net	-28	59	-3.09
Net Cash From Investing Activities	-219	-3.32	-17
Net Cash From Continuing Investing Activities	-219	-3.32	-17
Purchase of Property, Plant & Equipment	-4.05	-3.48	-2.15
Purchase of Investments	-398	-55	-139
Sale and/or Maturity of Investments	183	55	124
Net Cash From Financing Activities	164	187	-0.69
Net Cash From Continuing Financing Activities	164	187	-0.69
Repayment of Debt	0.00	-47	-74
Repurchase of Common Equity	-0.67	-0.45	-0.60
Issuance of Debt	0.00	5.30	74
Issuance of Common Equity	163	226	0.00
Other Financing Activities, net	1.38	3.17	-0.04
Effect of Exchange Rate Changes	0.00	0.00	0.00
Cash Interest Paid	0.00	1.41	2.60

This table details how cash moves in and out of EyePoint Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	20	-11	-180	-10	148	-6.56	34	10	20	-6.77
Net Cash From Operating Activities	-36	-39	-20	-31	-23	-15	57	-17	-13	-13
Net Cash From Continuing Operating Activities	-36	-39	-20	-31	-23	-15	57	-17	-13	-13
Net Income / (Loss) Continuing Operations	-41	-29	-31	-29	-14	-13	-23	-21	-43	-18
Consolidated Net Income / (Loss)	-41	-29	-31	-29	-14	-13	-23	-21	-43	-18
Depreciation Expense	0.47	0.41	0.36	0.30	0.11	0.12	0.13	0.11	0.13	0.10
Amortization Expense	-1.81	-1.88	-1.69	-0.58	-0.52	-0.04	-0.05	-0.24	-0.14	0.40
Non-Cash Adjustments To Reconcile Net Income	7.90	7.45	8.70	13	3.12	4.10	3.64	3.24	26	3.20
Changes in Operating Assets and Liabilities, net	-1.01	-16	3.28	-14	-12	-6.76	76	1.23	4.79	1.59
Net Cash From Investing Activities	-96	16	-160	21	-47	-1.72	13	32	33	6.27
Net Cash From Continuing Investing Activities	-96	16	-160	21	-47	-1.72	13	32	33	6.27
Purchase of Property, Plant & Equipment	-0.38	-1.57	-0.90	-1.19	-0.88	-1.72	-0.40	-0.48	-0.59	-1.20
Purchase of Investments	-164	-49	-185	0.00	-49	-	-2.92	-2.93	-13	-34
Sale and/or Maturity of Investments	69	67	26	22	3.00	-	17	36	47	41
Net Cash From Financing Activities	152	12	0.33	0.12	218	10	-37	-5.12	-0.06	0.09
Net Cash From Continuing Financing Activities	152	12	0.33	0.12	218	10	-37	-5.12	-0.06	0.09
Repayment of Debt	0.07	-0.07	-	0.00	-	-	-37	-10	-11	-10
Repurchase of Common Equity	-0.37	-0.31	0.09	-0.09	-0.04	-0.42	-	0.00	-	-0.03
Issuance of Common Equity	152	12	-	-	216	9.97	-	-	-	-
Other Financing Activities, net	0.46	0.17	0.55	0.20	2.32	0.80	-0.01	0.06	-0.06	0.12

This table presents EyePoint Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	418	355	180
Total Current Assets	383	345	173
Cash & Equivalents	100	281	96
Short-Term Investments	271	50	49
Accounts Receivable	0.61	0.81	16
Inventories, net	2.31	3.91	2.89
Prepaid Expenses	9.48	9.04	9.86
Plant, Property, & Equipment, net	8.18	5.25	1.36
Total Noncurrent Assets	27	5.13	6.19
Intangible Assets	0.00	0.00	0.00
Other Noncurrent Operating Assets	27	4.98	6.04
Other Noncurrent Nonoperating Assets	0.15	0.15	0.15
Total Liabilities & Shareholders' Equity	418	355	180
Total Liabilities	82	89	84
Total Current Liabilities	49	63	35
Short-Term Debt	0.00	0.00	10
Accounts Payable	12	6.50	5.92
Accrued Expenses	18	18	16
Current Deferred Revenue	18	39	1.21
Other Current Liabilities	1.44	0.65	0.58
Total Noncurrent Liabilities	33	26	49
Long-Term Debt	0.00	0.00	29
Noncurrent Deferred Revenue	11	21	14
Other Noncurrent Operating Liabilities	22	4.91	6.58
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	337	266	96
Total Preferred & Common Equity	337	266	96
Preferred Stock	0.00	0.00	0.00
Total Common Equity	337	266	96
Common Stock	1,208	1,008	767
Retained Earnings	-873	-742	-671
Accumulated Other Comprehensive Income / (Loss)	1.03	0.86	0.79

This table presents EyePoint Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	301	324	329	160	176	155	220
Total Current Assets	269	295	318	150	167	146	192
Cash & Equivalents	80	91	271	133	140	106	75
Short-Term Investments	174	189	28	2.98	2.94	17	82
Accounts Receivable	0.38	1.38	3.02	0.48	11	10	21
Inventories, net	2.81	3.67	4.26	4.58	4.26	4.07	3.53
Prepaid Expenses	12	9.64	11	9.09	9.37	9.08	10
Plant, Property, & Equipment, net	8.39	6.90	6.68	4.48	2.87	2.61	1.02
Total Noncurrent Assets	24	22	4.86	5.40	5.66	5.93	27
Intangible Assets	0.00	0.00	0.00	0.00	0.00	0.00	21
Other Noncurrent Operating Assets	24	22	4.71	5.25	5.51	5.78	6.32
Other Noncurrent Nonoperating Assets	0.15	0.15	0.15	0.15	0.15	0.15	0.15
Total Liabilities & Shareholders' Equity	301	324	329	160	176	155	220
Total Liabilities	82	96	79	101	118	76	84
Total Current Liabilities	49	62	63	64	69	27	34
Short-Term Debt	0.00	0.00	0.00	0.00	0.00	5.30	10
Accounts Payable	7.34	14	7.08	9.58	11	9.45	6.11
Accrued Expenses	14	13	16	13	15	10	16
Current Deferred Revenue	26	33	38	40	42	1.24	1.17
Other Current Liabilities	1.29	1.13	1.18	1.06	0.97	0.77	0.50
Total Noncurrent Liabilities	33	34	17	38	49	49	50
Long-Term Debt	0.00	0.00	0.00	0.00	0.00	29	29
Noncurrent Deferred Revenue	11	12	12	32	44	13	14
Other Noncurrent Operating Liabilities	22	22	4.62	5.19	5.46	6.32	6.84
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	219	228	250	59	57	78	136
Total Preferred & Common Equity	219	228	250	59	57	78	136
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	219	228	250	59	57	78	136
Common Stock	1,049	1,030	1,021	786	772	770	764
Retained Earnings	-832	-802	-771	-728	-715	-693	-628
Accumulated Other Comprehensive Income / (Loss)	1.17	0.79	0.84	0.84	0.84	0.84	0.65

This table displays calculated financial ratios and metrics derived from EyePoint Pharmaceuticals' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-5.97%	11.14%	12.09%
EBITDA Growth	-97.31%	28.35%	-85.36%
EBIT Growth	-91.97%	30.14%	-77.34%
NOPAT Growth	-94.30%	24.66%	-80.25%
Net Income Growth	-84.86%	30.77%	-75.04%
EPS Growth	-27.47%	33.58%	-34.98%
Operating Cash Flow Growth	-6,832.05%	102.88%	-29.76%
Free Cash Flow Firm Growth	-3,610.32%	107.26%	-42.46%
Invested Capital Growth	46.73%	-658.09%	-192.68%
Revenue Q/Q Growth	-5.34%	8.22%	-2.38%
EBITDA Q/Q Growth	-26.37%	29.20%	-36.36%
EBIT Q/Q Growth	-26.36%	29.61%	-33.79%
NOPAT Q/Q Growth	-24.69%	26.73%	-34.74%
Net Income Q/Q Growth	-26.36%	29.31%	-30.70%
EPS Q/Q Growth	-16.58%	30.27%	-30.48%
Operating Cash Flow Q/Q Growth	-11.23%	-84.87%	5.91%
Free Cash Flow Firm Q/Q Growth	-6.60%	-84.60%	15.03%
Invested Capital Q/Q Growth	1.84%	16.33%	-145.85%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	79.89%
EBITDA Margin	-312.39%	-148.88%	-230.94%
Operating Margin	-337.06%	-163.13%	-240.65%
EBIT Margin	-302.19%	-148.02%	-235.50%
Profit (Net Income) Margin	-302.43%	-153.84%	-246.97%
Tax Burden Percent	100.07%	100.12%	100.00%
Interest Burden Percent	100.01%	103.81%	104.87%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-20,634.88%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-20,611.67%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	20,562.04%
Return on Equity (ROE)	-43.42%	-39.04%	-72.84%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-33.81%	-25.44%	-43.95%
Return on Assets (ROA)	-33.83%	-26.44%	-46.09%
Return on Common Equity (ROCE)	-43.42%	-39.04%	-72.84%
Return on Equity Simple (ROE_SIMPLE)	-38.89%	-26.58%	-106.11%
Net Operating Profit after Tax (NOPAT)	-102	-53	-70
NOPAT Margin	-235.94%	-114.19%	-168.45%
Net Nonoperating Expense Percent (NNEP)	-8.19%	-8.37%	-23.21%
Return On Investment Capital (ROIC_SIMPLE)	-30.34%	-19.73%	-
Cost of Revenue to Revenue	0.00%	0.00%	20.11%
SG&A Expenses to Revenue	120.99%	87.14%	84.09%
R&D to Revenue	307.18%	140.51%	119.90%
Operating Expenses to Revenue	437.06%	263.13%	320.54%
Earnings before Interest and Taxes (EBIT)	-131	-68	-98
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-135	-69	-96
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.51	3.06	1.24
Price to Tangible Book Value (P/TBV)	1.51	3.06	1.24
Price to Revenue (P/Rev)	11.75	17.73	2.88
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.18	10.54	0.35
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	258.64	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	128.56	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.41
Long-Term Debt to Equity	0.00	0.00	0.30
Financial Leverage	-1.17	-1.20	-1.00
Leverage Ratio	1.28	1.48	1.58
Compound Leverage Factor	1.28	1.53	1.66
Debt to Total Capital	0.00%	0.00%	29.22%
Short-Term Debt to Total Capital	0.00%	0.00%	7.69%
Long-Term Debt to Total Capital	0.00%	0.00%	21.53%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	70.78%
Debt to EBITDA	0.00	0.00	-0.42
Net Debt to EBITDA	0.00	0.00	1.10
Long-Term Debt to EBITDA	0.00	0.00	-0.31
Debt to NOPAT	0.00	0.00	-0.57
Net Debt to NOPAT	0.00	0.00	1.50
Long-Term Debt to NOPAT	0.00	0.00	-0.42
Altman Z-Score	0.83	3.03	-4.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.81	5.45	5.00
Quick Ratio	7.57	5.25	4.63
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-132	3.77	-52
Operating Cash Flow to CapEx	-3,115.15%	53.83%	-3,023.49%
Free Cash Flow to Firm to Interest Expense	-9,458.06	1.45	-10.94
Operating Cash Flow to Interest Expense	-9,016.14	0.72	-13.69
Operating Cash Flow Less CapEx to Interest Expense	-9,305.57	-0.62	-14.14
Efficiency Ratios	-	-	-
Asset Turnover	0.11	0.17	0.19
Accounts Receivable Turnover	61.29	5.64	2.45
Inventory Turnover	0.00	0.00	2.56
Fixed Asset Turnover	6.45	13.92	45.10
Accounts Payable Turnover	0.00	0.00	1.25
Days Sales Outstanding (DSO)	5.96	64.67	149.23
Days Inventory Outstanding (DIO)	0.00	0.00	142.52
Days Payable Outstanding (DPO)	0.00	0.00	291.61
Cash Conversion Cycle (CCC)	5.96	64.67	0.14
Capital & Investment Metrics	-	-	-
Invested Capital	-35	-65	-8.56
Invested Capital Turnover	-0.87	-1.25	122.50
Increase / (Decrease) in Invested Capital	30	-56	-18
Enterprise Value (EV)	138	485	15
Market Capitalization	508	816	119
Book Value per Share	$4.93	$7.54	$2.83
Tangible Book Value per Share	$4.93	$7.54	$2.83
Total Capital	337	266	136
Total Debt	0.00	0.00	40
Total Long-Term Debt	0.00	0.00	29
Net Debt	-371	-331	-105
Capital Expenditures (CapEx)	4.05	3.48	2.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-37	-50	4.19
Debt-free Net Working Capital (DFNWC)	334	282	149
Net Working Capital (NWC)	334	282	138
Net Nonoperating Expense (NNE)	29	18	33
Net Nonoperating Obligations (NNO)	-371	-331	-105
Total Depreciation and Amortization (D&A)	-4.41	-0.39	1.89
Debt-free, Cash-free Net Working Capital to Revenue	-84.71%	-107.59%	10.11%
Debt-free Net Working Capital to Revenue	772.44%	611.80%	359.26%
Net Working Capital to Revenue	772.44%	611.80%	333.96%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.32)	($1.82)	($2.74)
Adjusted Weighted Average Basic Shares Outstanding	56.30M	38.90M	37.32M
Adjusted Diluted Earnings per Share	($2.32)	($1.82)	($2.74)
Adjusted Weighted Average Diluted Shares Outstanding	56.30M	38.90M	37.32M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	68.73M	49.83M	34.30M
Normalized Net Operating Profit after Tax (NOPAT)	-102	-53	-55
Normalized NOPAT Margin	-235.94%	-114.19%	-133.46%
Pre Tax Income Margin	-302.22%	-153.66%	-246.97%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-9,340.43	-26.26	-20.54
NOPAT to Interest Expense	-7,292.70	-20.26	-14.69
EBIT Less CapEx to Interest Expense	-9,629.86	-27.60	-20.99
NOPAT Less CapEx to Interest Expense	-7,582.13	-21.60	-15.14
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.51%	-0.64%	-0.59%

This table displays calculated financial ratios and metrics derived from EyePoint Pharmaceuticals' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-17.39%	-30.77%	4.09%	52.08%	33.18%	51.84%	-21.27%	-17.33%	-8.76%	10.52%
EBITDA Growth	-195.56%	-145.92%	-52.71%	-44.24%	66.20%	27.37%	-15.29%	-17.65%	-148.41%	-19.50%
EBIT Growth	-194.63%	-132.80%	-45.83%	-43.89%	67.15%	28.98%	-12.11%	-11.68%	-136.48%	-16.01%
NOPAT Growth	-176.62%	-127.45%	-51.78%	-54.59%	62.61%	21.74%	-18.45%	-17.88%	-142.33%	-20.15%
Net Income Growth	-193.63%	-132.80%	-34.49%	-38.37%	67.55%	31.53%	-18.11%	-0.90%	-123.61%	-10.33%
EPS Growth	-103.13%	-63.64%	4.92%	1.79%	72.41%	32.65%	-17.31%	0.00%	-70.59%	15.52%
Operating Cash Flow Growth	-55.13%	-156.70%	-135.39%	-85.16%	-83.58%	-15.74%	398.19%	16.48%	24.48%	-68.69%
Free Cash Flow Firm Growth	-238.13%	-175.76%	-164.48%	67.31%	449.86%	486.90%	600.08%	175.64%	-23.21%	-334.58%
Invested Capital Growth	46.73%	54.59%	39.02%	-417.48%	-658.09%	-515.39%	-533.51%	-161.92%	-192.68%	101.07%
Revenue Q/Q Growth	10.11%	11.05%	-18.89%	-16.71%	-7.72%	66.96%	18.51%	-27.06%	5.20%	-13.43%
EBITDA Q/Q Growth	-38.30%	4.13%	-8.80%	-104.88%	-15.08%	40.47%	-2.76%	51.98%	-147.24%	5.49%
EBIT Q/Q Growth	-40.65%	4.75%	-5.27%	-108.93%	-11.13%	40.33%	-3.86%	52.30%	-140.29%	5.81%
NOPAT Q/Q Growth	-38.14%	5.20%	-3.68%	-103.75%	-13.59%	36.74%	-5.60%	50.72%	-137.74%	4.26%
Net Income Q/Q Growth	-41.00%	4.75%	-5.27%	-107.70%	-11.79%	44.97%	-8.30%	51.29%	-135.90%	5.08%
EPS Q/Q Growth	-20.37%	6.90%	-5.45%	-71.88%	3.03%	45.90%	-8.93%	51.72%	-136.73%	5.77%
Operating Cash Flow Q/Q Growth	8.15%	-93.42%	35.27%	-34.89%	-51.99%	-126.66%	438.72%	-33.74%	4.17%	31.31%
Free Cash Flow Firm Q/Q Growth	5.02%	-13.46%	-445.18%	-62.87%	-47.90%	-3.44%	795.70%	177.65%	42.39%	-24.81%
Invested Capital Q/Q Growth	1.84%	32.41%	-5.10%	23.60%	16.33%	9.23%	-791.87%	-11.92%	-145.85%	-5.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	124.99%	93.01%	85.22%	93.50%	125.91%	92.09%	80.32%	91.67%	37.82%	100.00%
EBITDA Margin	-367.95%	-292.94%	-339.31%	-252.96%	-102.84%	-82.46%	-231.27%	-266.71%	-405.16%	-172.40%
Operating Margin	-390.40%	-311.17%	-364.52%	-285.18%	-116.58%	-94.71%	-249.98%	-280.54%	-415.26%	-183.76%
EBIT Margin	-356.36%	-278.99%	-325.27%	-250.63%	-99.91%	-82.96%	-232.16%	-264.90%	-405.12%	-177.37%
Profit (Net Income) Margin	-357.26%	-278.99%	-325.27%	-250.63%	-100.51%	-82.96%	-251.73%	-275.47%	-412.53%	-183.98%
Tax Burden Percent	100.22%	100.00%	100.00%	100.00%	100.59%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.03%	100.00%	100.00%	100.00%	100.00%	100.00%	108.43%	103.99%	101.83%	103.73%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,653.48%	-35,607.41%	-390.39%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,648.41%	-35,598.25%	-384.88%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2,584.79%	35,512.53%	337.92%
Return on Equity (ROE)	-43.42%	-74.68%	-60.81%	-48.07%	-39.04%	-102.73%	-101.57%	-68.69%	-94.88%	-52.47%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-437.52%
Operating Return on Assets (OROA)	-39.87%	-55.33%	-65.58%	-51.82%	-17.17%	-18.54%	-42.37%	-52.82%	-75.60%	-38.70%
Return on Assets (ROA)	-39.97%	-55.33%	-65.58%	-51.82%	-17.27%	-18.54%	-45.95%	-54.92%	-76.99%	-40.15%
Return on Common Equity (ROCE)	-43.42%	-74.68%	-60.81%	-48.07%	-39.04%	-102.73%	-101.57%	-68.69%	-94.88%	-52.47%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-47.35%	-38.03%	-31.57%	0.00%	-170.84%	-185.04%	-130.68%	0.00%	-57.38%
Net Operating Profit after Tax (NOPAT)	-32	-23	-24	-23	-11	-10	-16	-15	-31	-13
NOPAT Margin	-273.28%	-217.82%	-255.17%	-199.63%	-81.61%	-66.30%	-174.99%	-196.38%	-290.68%	-128.63%
Net Nonoperating Expense Percent (NNEP)	-2.77%	-3.30%	-3.14%	-3.08%	-1.22%	-2.00%	-5.09%	-5.08%	-9.17%	-5.51%
Return On Investment Capital (ROIC_SIMPLE)	-9.41%	-	-	-	-4.30%	-	-	-	-	-
Cost of Revenue to Revenue	-24.99%	6.99%	14.78%	6.50%	-25.91%	7.91%	19.68%	8.33%	62.18%	0.00%
SG&A Expenses to Revenue	108.19%	123.24%	134.54%	120.69%	80.18%	69.44%	99.46%	120.29%	80.70%	92.01%
R&D to Revenue	374.72%	280.71%	314.68%	257.95%	127.97%	114.22%	172.76%	177.25%	147.56%	111.49%
Operating Expenses to Revenue	515.39%	404.18%	449.74%	378.69%	242.49%	186.80%	330.30%	372.21%	453.08%	283.76%
Earnings before Interest and Taxes (EBIT)	-41	-29	-31	-29	-14	-13	-21	-20	-43	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-43	-31	-32	-30	-14	-13	-21	-20	-43	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.51	1.95	1.98	4.12	3.06	4.77	5.21	1.29	1.24	1.98
Price to Tangible Book Value (P/TBV)	1.51	1.95	1.98	4.12	3.06	4.77	5.21	1.29	1.24	2.33
Price to Revenue (P/Rev)	11.75	9.35	8.99	20.59	17.73	6.57	7.99	2.53	2.88	6.35
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.14
Enterprise Value to Revenue (EV/Rev)	3.18	3.80	3.43	14.61	10.54	3.37	4.18	0.33	0.35	3.58
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	258.64	11.58	10.78	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	128.56	5.86	5.09	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.44	0.41	0.29
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37	0.30	0.21
Financial Leverage	-1.17	-1.41	-1.48	-1.18	-1.20	-1.30	-1.32	-0.98	-1.00	-0.88
Leverage Ratio	1.28	1.66	1.75	1.47	1.48	1.95	1.96	1.63	1.58	1.70
Compound Leverage Factor	1.28	1.66	1.75	1.47	1.48	1.95	2.13	1.69	1.61	1.76
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	30.66%	29.22%	22.56%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.68%	7.69%	5.95%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	25.98%	21.53%	16.61%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	69.34%	70.78%	77.44%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.35	-0.42	-0.57
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.89	1.10	1.68
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.30	-0.31	-0.42
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.48	-0.57	-0.77
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.22	1.50	2.27
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.41	-0.42	-0.57
Altman Z-Score	1.54	-0.04	0.07	5.30	3.54	-4.06	-3.70	-4.73	-3.99	-1.28
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.81	5.50	4.75	5.08	5.45	2.35	2.42	5.36	5.00	5.61
Quick Ratio	7.57	5.21	4.53	4.83	5.25	2.14	2.23	4.88	4.63	5.20
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-62	-65	-58	17	45	86	89	9.96	-13	-22
Operating Cash Flow to CapEx	-9,335.68%	-2,479.54%	-2,242.00%	-2,610.64%	-2,617.10%	-883.95%	14,399.75%	-3,478.31%	-2,151.79%	-1,096.49%
Free Cash Flow to Firm to Interest Expense	-4,427.31	0.00	0.00	0.00	0.00	0.00	50.05	12.26	-16.42	-33.63
Operating Cash Flow to Interest Expense	-2,560.64	0.00	0.00	0.00	0.00	0.00	32.00	-20.73	-16.12	-19.84
Operating Cash Flow Less CapEx to Interest Expense	-2,588.07	0.00	0.00	0.00	0.00	0.00	31.78	-21.33	-16.87	-21.65
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.11	0.20	0.20	0.21	0.17	0.22	0.18	0.20	0.19	0.22
Accounts Receivable Turnover	61.29	106.19	8.18	7.45	5.64	3.98	2.23	2.65	2.45	2.46
Inventory Turnover	0.00	1.05	1.10	1.14	0.00	2.51	2.39	1.94	2.56	1.19
Fixed Asset Turnover	6.45	7.10	10.31	10.77	13.92	15.48	18.74	25.23	45.10	53.86
Accounts Payable Turnover	0.00	0.46	0.35	0.57	0.00	1.30	1.01	0.86	1.25	0.75
Days Sales Outstanding (DSO)	5.96	3.44	44.64	49.03	64.67	91.67	163.99	137.64	149.23	148.35
Days Inventory Outstanding (DIO)	0.00	346.07	332.06	319.90	0.00	145.31	152.71	188.03	142.52	307.40
Days Payable Outstanding (DPO)	0.00	793.13	1,046.99	635.16	0.00	281.23	361.20	425.34	291.61	483.80
Cash Conversion Cycle (CCC)	5.96	-443.63	-670.29	-266.23	64.67	-44.25	-44.50	-99.67	0.14	-28.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-35	-35	-52	-50	-65	-78	-85	-9.58	-8.56	19
Invested Capital Turnover	-0.87	-0.81	-0.73	-1.69	-1.25	-1.44	-1.14	13.51	122.50	3.04
Increase / (Decrease) in Invested Capital	30	42	33	-40	-56	-96	-105	-25	-18	9.38
Enterprise Value (EV)	138	174	173	731	485	144	156	13	15	152
Market Capitalization	508	428	453	1,030	816	280	298	101	119	270
Book Value per Share	$4.93	$4.09	$4.38	$5.02	$7.54	$1.68	$1.67	$2.29	$2.83	$4.00
Tangible Book Value per Share	$4.93	$4.09	$4.38	$5.02	$7.54	$1.68	$1.67	$2.29	$2.83	$3.39
Total Capital	337	219	228	250	266	59	57	113	136	176
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	35	40	40
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29	29	29
Net Debt	-371	-254	-280	-299	-331	-136	-143	-88	-105	-118
Capital Expenditures (CapEx)	0.38	1.57	0.90	1.19	0.88	1.72	0.40	0.48	0.59	1.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-37	-34	-47	-44	-50	-50	-44	1.63	4.19	11
Debt-free Net Working Capital (DFNWC)	334	220	233	255	282	86	98	124	149	168
Net Working Capital (NWC)	334	220	233	255	282	86	98	119	138	158
Net Nonoperating Expense (NNE)	9.73	6.44	6.64	5.96	2.65	2.53	6.99	6.08	13	5.54
Net Nonoperating Obligations (NNO)	-371	-254	-280	-299	-331	-136	-143	-88	-105	-118
Total Depreciation and Amortization (D&A)	-1.34	-1.47	-1.33	-0.27	-0.41	0.08	0.08	-0.14	-0.01	0.50
Debt-free, Cash-free Net Working Capital to Revenue	-84.71%	-74.46%	-94.10%	-88.40%	-107.59%	-116.98%	-118.75%	4.09%	10.11%	26.08%
Debt-free Net Working Capital to Revenue	772.44%	480.73%	462.04%	510.06%	611.80%	202.87%	263.04%	311.89%	359.26%	396.84%
Net Working Capital to Revenue	772.44%	480.73%	462.04%	510.06%	611.80%	202.87%	263.04%	298.58%	333.96%	372.15%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.65)	($0.54)	($0.58)	($0.55)	($0.32)	($0.33)	($0.61)	($0.56)	($1.16)	($0.49)
Adjusted Weighted Average Basic Shares Outstanding	56.30M	54.45M	53.21M	52.91M	38.90M	38.34M	37.58M	37.49M	37.32M	37.34M
Adjusted Diluted Earnings per Share	($0.65)	($0.54)	($0.58)	($0.55)	($0.32)	($0.33)	($0.61)	($0.56)	($1.16)	($0.49)
Adjusted Weighted Average Diluted Shares Outstanding	56.30M	54.45M	53.21M	52.91M	38.90M	38.34M	37.58M	37.49M	37.32M	37.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($1.16)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	68.73M	68.25M	53.52M	52.08M	49.83M	35.31M	34.98M	34.30M	34.30M	34.08M
Normalized Net Operating Profit after Tax (NOPAT)	-32	-23	-24	-23	-11	-10	-16	-15	-31	-13
Normalized NOPAT Margin	-273.28%	-217.82%	-255.17%	-199.63%	-81.61%	-66.30%	-174.99%	-196.38%	-290.68%	-128.63%
Pre Tax Income Margin	-356.48%	-278.99%	-325.27%	-250.63%	-99.91%	-82.96%	-251.73%	-275.47%	-412.53%	-183.98%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2,949.64	0.00	0.00	0.00	0.00	0.00	-11.86	-25.06	-54.64	-26.82
NOPAT to Interest Expense	-2,261.95	0.00	0.00	0.00	0.00	0.00	-8.94	-18.58	-39.20	-19.45
EBIT Less CapEx to Interest Expense	-2,977.07	0.00	0.00	0.00	0.00	0.00	-12.08	-25.66	-55.39	-28.63
NOPAT Less CapEx to Interest Expense	-2,289.38	0.00	0.00	0.00	0.00	0.00	-9.16	-19.18	-39.95	-21.26
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.51%	-0.33%	-0.52%	-0.68%	-0.64%	-0.41%	-0.02%	-0.24%	-0.59%	-0.77%

Frequently Asked Questions About EyePoint Pharmaceuticals' Financials

When does EyePoint Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, EyePoint Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has EyePoint Pharmaceuticals' net income changed over the last 2 years?

EyePoint Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$130.87 million in 2024, rising from -$102.25 million in 2022. The previous period was -$70.80 million in 2023. Find out what analysts predict for EyePoint Pharmaceuticals in the coming months.

What is EyePoint Pharmaceuticals's operating income?

EyePoint Pharmaceuticals's total operating income in 2024 was -$145.85 million, based on the following breakdown:

Total Gross Profit: $43.27 million
Total Operating Expenses: $189.13 million

How has EyePoint Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, EyePoint Pharmaceuticals' total revenue changed from $41.40 million in 2022 to $43.27 million in 2024, a change of 4.5%.

How much debt does EyePoint Pharmaceuticals have?

EyePoint Pharmaceuticals' total liabilities were at $81.96 million at the end of 2024, a 7.8% decrease from 2023, and a 2.4% decrease since 2022.

How much cash does EyePoint Pharmaceuticals have?

In the past 2 years, EyePoint Pharmaceuticals' cash and equivalents has ranged from $95.63 million in 2022 to $281.26 million in 2023, and is currently $99.70 million as of their latest financial filing in 2024.

How has EyePoint Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, EyePoint Pharmaceuticals' book value per share changed from 2.83 in 2022 to 4.93 in 2024, a change of 74.4%.

Related Companies

This page (NASDAQ:EYPT) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

EyePoint Pharmaceuticals (EYPT) Financials

Frequently Asked Questions About EyePoint Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

EyePoint Pharmaceuticals (EYPT) Financials

Annual Income Statements for EyePoint Pharmaceuticals

Quarterly Income Statements for EyePoint Pharmaceuticals

Annual Cash Flow Statements for EyePoint Pharmaceuticals

Quarterly Cash Flow Statements for EyePoint Pharmaceuticals

Annual Balance Sheets for EyePoint Pharmaceuticals

Quarterly Balance Sheets for EyePoint Pharmaceuticals

Annual Metrics And Ratios for EyePoint Pharmaceuticals

Quarterly Metrics And Ratios for EyePoint Pharmaceuticals

Frequently Asked Questions About EyePoint Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools